When querying ClinicalTrials.gov 5-amino-1mq status, lab investigators find that 5-Amino-1MQ remains an active subject of preclinical and in vitro research rather than completed FDA human trial phases. As a selective, membrane-permeable nicotinamide N-methyltransferase (NNMT) inhibitor, 5-Amino-1MQ is studied for raising intracellular NAD+ levels, optimizing mitochondrial bioenergetics, and regulating lipid accumulation in metabolic rodent models.
When querying ClinicalTrials.gov 5-amino-1mq status, lab investigators find that 5-Amino-1MQ remains an active subject of preclinical and in vitro research rather than completed FDA human trial phases. As a selective, membrane-permeable nicotinamide N-methyltransferase (NNMT) inhibitor, 5-Amino-1MQ is studied for raising intracellular NAD+ levels, optimizing mitochondrial bioenergetics, and regulating lipid accumulation in metabolic rodent models.
A formal search for a clinicaltrials.gov 5-amino-1mq entry reveals that the compound is primarily documented across basic science, translational biochemistry, and preclinical rodent models rather than completed phase 3 human clinical trials. While investigators search public databases for human trial registrations under terms like clinicaltrials.gov 5-amino-1mq, the small molecule's core literature originates from academic medical centers evaluating novel nicotinamide N-methyltransferase (NNMT) inhibitor kinetics.
Nicotinamide N-methyltransferase is a cytosolic enzyme responsible for catalyzing the methylation of nicotinamide (NAM) using S-adenosylmethionine (SAM) as a methyl donor. By inhibiting this enzymatic reaction, researchers observe a reduction in 1-methylnicotinamide (1-MNA) synthesis and a concurrent conservation of intracellular NAD+ pools. Consequently, primary research workflows utilize high-purity 5-Amino-1MQ to quantify cellular energy expenditure, mitochondrial flux, and adipocyte expansion in vitro without relying on human clinical trial dosing profiles.
For laboratory researchers seeking validated references, understanding the current state of clinicaltrials.gov 5-amino-1mq listings requires distinguishing between investigational drug status and chemical research probes. 5-Amino-1MQ functions primarily as a highly specific tool molecule designed to elucidate metabolic signaling pathways in preclinical disease models.
When evaluating a potential 5-amino-1mq human clinical trial nnmt inhibitor framework, investigators must analyze the foundational animal and cell culture studies that precede human evaluation. Preclinical trials in diet-induced obese rodent models demonstrate that targeted NNMT inhibition leads to decreased body weight gain, reduced white adipose tissue mass, and elevated basal metabolic rates without altering overall food intake.
In cell culture models, application of a high-purity NNMT inhibitor suppresses adipocyte hypertrophy and promotes GLUT4 expression, driving glucose utilization into oxidative pathways. Because published literature lacks broad 5-amino-1mq clinical trial humans nnmt inhibitor dataset releases from phase II or phase III registration trials, research groups rely on rigorous in vitro assays to map cellular toxicity thresholds, pharmacokinetic profiles, and enzyme binding affinities.
PX1 Research supplies synthetic compounds exclusively to academic and institutional laboratories evaluating these pathways. Institutional protocols requiring precise standard control samples can access our complete research library for comparative methodologies or review verified lot documentation prior to initiating high-throughput screening runs.
The enzymatic mechanism underlying 5-Amino-1MQ centers on its competitive inhibition of NNMT. Overexpression of NNMT in adipose, liver, and cancer cell tissues correlates with depleted intracellular NAD+ concentrations and disrupted S-adenosylmethionine to S-adenosylhomocysteine (SAM/SAH) methylation ratios. By blocking NNMT activity, 5-Amino-1MQ prevents the irreversible conversion of nicotinamide into 1-MNA, directing nicotinamide into the NAD+ salvage pathway via nicotinamide phosphoribosyltransferase (NAMPT).
Preclinical data indicate that elevated NAD+ concentrations activate silent information regulator two homolog 1 (SIRT1) and poly(ADP-ribose) polymerase (PARP) enzymes, downstream drivers of mitochondrial biogenesis and DNA repair mechanism studies. Researchers investigating mitochondrial bioenergetics often combine 5-Amino-1MQ assays with secondary energy pathways to measure changes in oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) across cultured cell populations.
Because NNMT also dictates epigenetic methylation capacity by regulating universal methyl donor availability, screening with 5-Amino-1MQ allows laboratories to examine histone methylation markers and transcriptomic shifts in metabolic signaling networks. Detailed structural dynamics are cataloged across our extended research peptides catalog.
In rodent models of metabolic dysfunction, selective NNMT inhibition by 5-Amino-1MQ demonstrates distinct alterations in cellular substrate utilization. Adipocytes treated with 5-Amino-1MQ display increased expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and uncoupling protein 1 (UCP1), signaling an up-regulation of thermogenic activity and mitochondrial respiration.
These mitochondrial adaptations support enhanced beta-oxidation of fatty acids within metabolic tissue samples. Researchers observing lipid storage mechanics report that NNMT knockdown or chemical inhibition via 5-Amino-1MQ reduces intracellular triglyceride accumulation in 3T3-L1 adipocyte lines. This makes the compound a central reagent in obesity, insulin resistance, and hepatic steatosis laboratory studies.
To maintain consistency across longitudinal cellular studies, laboratories require clean chemical reagents free from toxic heavy metals, residual solvents, or structural isomers. PX1 Research ensures every batch undergoes comprehensive analytical testing, facilitating reliable replication of published preclinical literature.
When designing protocols to investigate cell metabolism, researchers frequently compare 5-Amino-1MQ against other novel metabolic regulators. While 5-Amino-1MQ directly targets enzymatic NNMT inhibition to preserve NAD+ pools, peptide ligands such as MOTS-c function as mitochondrially derived peptides that translocate to the nucleus to regulate metabolic homeostasis under stress conditions. Similarly, small molecules like AICAR stimulate 5'-AMP-activated protein kinase (AMPK) directly, bypassing the salvaging of nicotinamide to drive fatty acid oxidation.
In targeted mitochondrial structural models, researchers also pair metabolic regulators with cardiolipin-protective peptides like SS-31 to differentiate between enzyme-mediated NAD+ salvage and direct inner mitochondrial membrane stabilization. Reviewing these distinct molecular targets side-by-side helps lab managers select the precise probe for their specific hypothesis:
• 5-Amino-1MQ: Small molecule NNMT inhibitor; raises intracellular NAD+ by blocking NAM methylation. • MOTS-c: Mitochondrial-derived peptide; modulates nuclear gene expression during metabolic stress. • AICAR: Adenosine analog; directly activates AMPK signaling networks independent of NAD+ baseline. • SS-31: Selective mitochondria-targeted peptide; binds cardiolipin to restore electron transport chain efficiency. For larger multi-target comparative projects, laboratory buyers can establish bulk accounts through our wholesale lab portal to streamline acquisition of validated research compounds.
High-throughput screening and quantitative enzymatic assays depend on ultra-pure chemical standards. When ordering 5-Amino-1MQ for laboratory research use only, analytical integrity dictates experimental reproducibility. Impurities or unreacted synthesis precursors can introduce off-target cytotoxic effects or false-positive enzymatic inhibition in cell culture media.
PX1 Research sets stringent manufacturing standards for every lot produced in our GMP-compliant, USA-based facilities. Every batch undergoes rigorous quality control verified by independent ISO 17025 accredited laboratories. We provide raw data verify purity via High-Performance Liquid Chromatography (HPLC) and confirm structural molecular weight through Mass Spectrometry (MS).
Furthermore, our compounds undergo routine bacterial endotoxin testing to guarantee compatibility with sensitive cell lines and primary culture systems. Researchers can download lot-specific Certificates of Analysis (COAs) directly prior to study initiation.
5-Amino-1MQ (1-methylquinolin-1-ium-5-amine; quinolinium derivative) exhibits distinct solubility dynamics compared to standard hydrophilic peptides. In solid laboratory form, 5-Amino-1MQ should be stored desiccated at -20°C, protected from light and moisture exposure to maintain chemical stability.
For reconstituted in vitro assays, 5-Amino-1MQ is soluble in organic solvents such as dimethyl sulfoxide (DMSO) and ethanol, as well as select buffered aqueous solutions depending on target pH and concentration parameters. Stock solutions prepared in DMSO should be aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles that can induce chemical degradation.
When handling powder or liquid concentrates, laboratory personnel must utilize standard personal protective equipment (PPE), including nitrile gloves, safety goggles, and chemical fume hoods. 5-Amino-1MQ is supplied strictly for in vitro laboratory research and animal models; it is not intended for human or veterinary administration.
Securing consistent laboratory reagents is vital to maintaining project timelines and institutional budgets. PX1 Research eliminates supply chain bottlenecks by operating fully equipped domestic distribution hubs in California and Arizona. Every order placed Monday through Friday before our daily cutoff ships same-day, ensuring rapid fulfillment for urgent research schedules.
Our dedication to transparency extends beyond chemical synthesis. By providing lot-traceable COAs, HPLC chromatograms, and MS spectra with every shipment, we empower researchers to verify compound purity before breaking micro-centrifuge seals. Whether executing preliminary target validation assays or scaling up multi-center animal models, institutions rely on PX1 for pure, USA-manufactured research chemicals.
Explore our complete catalog of small molecules, signaling probes, and research peptides to support your facility's biomedical discoveries.
Is there an active clinicaltrials.gov 5-amino-1mq trial registered for human subjects?
Currently, direct human clinical trial listings for 5-Amino-1MQ under ClinicalTrials.gov are limited, as the molecule remains predominantly in preclinical and in vitro research stages. Studies primarily focus on animal models evaluating NNMT enzyme inhibition, NAD+ conservation, and metabolic kinetics.
What is the primary mechanism of a 5-amino-1mq human clinical trial nnmt inhibitor study?
In preclinical research models, 5-Amino-1MQ acts as a selective inhibitor of nicotinamide N-methyltransferase (NNMT). Blocking this enzyme prevents the consumption of nicotinamide, leading to increased intracellular NAD+ levels and elevated cellular energy expenditure.
Has a 5-amino-1mq clinical trial humans nnmt inhibitor phase been completed by the FDA?
No, 5-Amino-1MQ has not completed FDA phase trials or received approval for human therapeutic use. It is synthesized and supplied strictly as a chemical probe for laboratory and preclinical research.
Where can I find 5-amino-1mq clinical trial data regarding fat metabolism?
Fat metabolism data for 5-Amino-1MQ comes from preclinical rodent models and adipocyte cell culture studies published in peer-reviewed journals. These studies demonstrate reduced adipocyte hypertrophy, increased GLUT4 expression, and altered lipid accumulation upon NNMT inhibition.
Why is 5-amino-1mq clinicaltrials.gov searching common among researchers?
Researchers search ClinicalTrials.gov to determine whether preclinical compounds targeting NNMT and NAD+ pathways have transitioned into human safety and pharmacokinetic trials. Tracking these queries helps laboratories contextualize translational research milestones.
How does 5-Amino-1MQ affect intracellular NAD+ levels in vitro?
By inhibiting NNMT, 5-Amino-1MQ stops the methylation of nicotinamide into 1-methylnicotinamide (1-MNA). Nicotinamide is then recycled via the NAMPT salvage pathway into NAD+, elevating cellular NAD+ concentrations.
How should lab-grade 5-Amino-1MQ be reconstituted for assays?
5-Amino-1MQ is typically reconstituted in organic solvents like DMSO or standard laboratory buffers depending on working concentration requirements. Stock solutions should be stored in single-use aliquots at -80°C to minimize degradation.
What quality testing does PX1 Research perform on 5-Amino-1MQ?
Every lot of 5-Amino-1MQ undergoes independent third-party testing in ISO 17025 accredited facilities. Verification includes High-Performance Liquid Chromatography (HPLC) for chemical purity, Mass Spectrometry (MS) for identity confirmation, and endotoxin analysis.
Where does PX1 Research manufacture and ship its research compounds?
All PX1 Research compounds are manufactured in domestic GMP-compliant US facilities and shipped directly from fulfillment centers in California and Arizona, offering same-day shipping M–F.
Is 5-Amino-1MQ available for bulk laboratory purchases?
Yes, PX1 Research provides volume tiers and institutional procurement options for university, biotech, and pharmaceutical laboratories through our wholesale program.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.